Azora Capital LP grew its stake in shares of Enfusion, Inc. (NYSE:ENFN – Free Report) by 6.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 29,827 shares of the company’s stock after buying an additional 1,890 shares during the period. Azora Capital LP’s holdings in Enfusion were worth $283,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Paloma Partners Management Co bought a new position in Enfusion in the third quarter valued at $157,000. PDT Partners LLC bought a new position in shares of Enfusion during the 3rd quarter valued at about $867,000. Martingale Asset Management L P increased its position in shares of Enfusion by 26.2% during the 3rd quarter. Martingale Asset Management L P now owns 74,360 shares of the company’s stock valued at $706,000 after purchasing an additional 15,424 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Enfusion by 9.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 365,512 shares of the company’s stock valued at $3,469,000 after buying an additional 31,743 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in Enfusion in the third quarter worth approximately $308,000. 81.05% of the stock is owned by institutional investors.
Enfusion Price Performance
Shares of NYSE ENFN opened at $9.94 on Monday. The stock has a market capitalization of $1.28 billion, a P/E ratio of 248.50, a PEG ratio of 3.72 and a beta of 0.93. Enfusion, Inc. has a one year low of $7.52 and a one year high of $10.45. The firm’s 50 day simple moving average is $9.32 and its two-hundred day simple moving average is $8.89.
About Enfusion
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
See Also
- Five stocks we like better than Enfusion
- Do ETFs Pay Dividends? What You Need to Know
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- How Can Investors Benefit From After-Hours Trading
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Ride Out The Recession With These Dividend KingsĀ
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding ENFN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN – Free Report).
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.